Immune Pathophysiology of Aplastic Anemia
- 1 October 2005
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 82 (3) , 196-200
- https://doi.org/10.1532/ijh97.05116
Abstract
Acquired aplastic anemia (AA) is considered an immune-mediated disease because approximately 70% of AA patients improve with immunosuppressive therapy. However, little is known about the inciting antigens or the mechanisms responsible for the destruction of hematopoietic stem cells by immune system attack. Recent advances in immunologic techniques have promoted our understanding of the pathogenesis of AA and have provided evidence that AA is an organ-specific T-cell-mediated disease localized in the bone marrow. Moreover, antibody screening of patients' serum with a complementary DNA library derived from hematopoietic cells has identified several proteins as candidate autoantigens in AA.Keywords
This publication has 42 references indexed in Scilit:
- Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria–type cellsBlood, 2004
- Excessive production of tumor necrosis factor‐alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemiaEuropean Journal of Haematology, 2004
- Autoantibodies frequently detected in patients with aplastic anemiaBlood, 2003
- Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor–negative cells: implications for paroxysmal nocturnal hemoglobinuriaBlood, 2002
- Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapyBlood, 2002
- A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndromeBritish Journal of Haematology, 2002
- Infliximab chimaeric anti‐tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromesBritish Journal of Haematology, 2002
- Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantationBone Marrow Transplantation, 2001
- Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells.The Journal of Experimental Medicine, 1994
- Treatment of Aplastic Anemia with Antilymphocyte Globulin and Methylprednisolone with or without CyclosporineNew England Journal of Medicine, 1991